Imaging end points for monitoring neuroprotection in Parkinson's disease
Identifieur interne : 001753 ( Main/Exploration ); précédent : 001752; suivant : 001754Imaging end points for monitoring neuroprotection in Parkinson's disease
Auteurs : David J. Brooks [Royaume-Uni]Source :
- Annals of Neurology [ 0364-5134 ] ; 2003.
Abstract
In this review, the potential role of positron emission tomography and single‐photon emission computed tomography as biological markers for following the progression of Parkinson's disease (PD) is discussed, and their value for assessing the efficacy of putative neuroprotective agents in PD is considered. It is concluded that functional imaging provides a valuable adjunct to clinical assessment when judging the efficacy of neuroprotective approaches to PD. Ann Neurol 2003;53: (suppl 3)S110–S119
Url:
DOI: 10.1002/ana.10480
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Imaging end points for monitoring neuroprotection in Parkinson's disease</title><author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BCFC852058D983C73E6E3B195D2EFDA70E73F81E</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1002/ana.10480</idno><idno type="url">https://api.istex.fr/document/BCFC852058D983C73E6E3B195D2EFDA70E73F81E/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002868</idno><idno type="wicri:Area/Main/Curation">002520</idno><idno type="wicri:Area/Main/Exploration">001753</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Imaging end points for monitoring neuroprotection in Parkinson's disease</title><author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2003">2003</date><biblScope unit="volume">53</biblScope><biblScope unit="issue">S3</biblScope><biblScope unit="supplement">3</biblScope><biblScope unit="page" from="S110">S110</biblScope><biblScope unit="page" to="S119">S119</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">BCFC852058D983C73E6E3B195D2EFDA70E73F81E</idno><idno type="DOI">10.1002/ana.10480</idno><idno type="ArticleID">ANA10480</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In this review, the potential role of positron emission tomography and single‐photon emission computed tomography as biological markers for following the progression of Parkinson's disease (PD) is discussed, and their value for assessing the efficacy of putative neuroprotective agents in PD is considered. It is concluded that functional imaging provides a valuable adjunct to clinical assessment when judging the efficacy of neuroprotective approaches to PD. Ann Neurol 2003;53: (suppl 3)S110–S119</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001753 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001753 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:BCFC852058D983C73E6E3B195D2EFDA70E73F81E
|texte= Imaging end points for monitoring neuroprotection in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |